The role of iron and iron chelators in anthracycline cardiotoxicity

Leukemia and Lymphoma

Volumn 11, Issue 3-4, 1993, Pages 207-214

  Hershko, C ^a   Link, G ^a   Tzahor, M ^a   Pinson, A ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Anthracyclines; Cardiotoxicity; Iron; Iron chelators

Indexed keywords

ANTHRACYCLINE; CHELATING AGENT; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; HYDROXYL RADICAL; IRON; RAZOXANE; SUPEROXIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; BREAST CANCER; CANCER; CARDIOTOXICITY; CONTROLLED STUDY; FEMALE; HEART MUSCLE CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; IRON OVERLOAD; MOUSE; NONHUMAN; RAT; REVIEW;

ANIMAL; ANTIBIOTICS, ANTHRACYCLINE; FREE RADICALS; HEART DISEASES; HUMAN; IRON; IRON CHELATING AGENTS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027489682     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199309086997     Document Type: Article

References (60)

1. The anthracycline antineoplastic drugs
2. Inhibition of DNA replication initiation by 4-nitroquinoline 1-oxide adriamycin and ethyleneimine
3. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro
4. Anthracycline glycoside-membrane interactions
5. Free radical formation by antitumor quinones
6. Biochemical determinants of adriamycin toxicity in mouse liver, heart and intestine
7. Are oxygen radicals responsible for the acute cardiotoxicity of doxorubicin
8. Influence of selenium on lipid peroxidation and cardiac functions in chronically adriamycin-treated rats
9. Structural requirements for anthracycline-induced cardiotoxicity and antitumor effects
10. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response
11. Modifying intracellular redox balance: an approach to improving therapeutic index
12. Subcellular effects of adriamycin in the heart: a concise review
13. The anticancer agent adriamycin can be actively cytotoxic without entering cells
14. A clinicopathologic analysis of adriamycin toxicity
15. Adriamycin cardiotoxicity: possible pathogenic mechanisms
16. Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardio-myopathy
17. Lysosornal alterations in heart and liver of mice treated with doxorubicin
18. 2+ binding and lipid peroxidation but depresses myocardial function
19. Adriamycin-induced cardiac damage in the mouse: a small animal model of cardiotoxicity. J
20. Modification by adenosine of the effect of adriamycin on myocardial cells in culture
21. Biochim
22. Iron in the heart: etiology and clinical significance
23. Thiolic sarcolemrnal proteins are a primary target of iron toxicity in cultured rat heart cells. American Society of Hematology Thirty-Fourth Annual Meeting. December 4–8, Anaheim, CA
24. Metal chelation therapy, oxygen radicals, and human disease
25. Oxygen toxicity, oxygen radicals, transition metals and disease
26. Ferric nitriloacetate: a potent stimulant of in vivo lipid peroxidation in mice
27. Effect of antioxidants on lipid peroxidation in iron-loaded rats
28. Acute ferrous sulfate hepatotoxicity in rats. An electron microscopic and biochemical study
29. Properties of liver mitochondria from iron-loaded rats
30. Hepatic mitochondrial oxidative metabolism in rats with chronic dietary iron overload
31. Characterization of iron-mediated peroxidative injury in isolated hepatic lysosomes
32. Organelle pathology in primary and secondary hemochromatosis with special reference to lysosomal changes
33. Haemosiderin and tissue damage
34. The role of free radical-mediated processes in oxygen-related damage in cultured murine myocardial cells
35. Effects of acute iron loading on contractility and spontaneous beating rate of cultured rat myocardial cells
36. Absence of generation of oxygen-containing free radicals with 4′-deoxydoxorubicin iron-cardiotoxic drug
37. Role of iron in anthracycline action
38. Adriamycin-iron catalysed phospholipid peroxidation: a reaction not involving Adriamycin or hydroxyl radicals
39. NADPH-and adriamycin-dependent microsomal release of iron and lipid peroxidation
40. Inhibition of the iron-catalysed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine
41. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action
42. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer
43. Antitumour activity in a series of bisDiketopiperazines
44. Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig
45. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-bis(3,5-dioxopiperazinyl-l-yl) propane (ICRF-187)
46. Comparison of the effectiveness of (±)-bis(3,5-dioxopiperazinyl-l-yl) propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles
47. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat
48. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943)
49. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer
50. Adri-amycin-induced free radical formation in the perfused rat heart: Implications for cardiotoxicity
51. Effect of iron loading on transmembrane potential, contraction and automaticity of rat ventricular muscle cells in culture
52. Heart cells in culture: a model of myocardial iron overload and chelation
53. Modification of iron uptake and lipid peroxidation by hypoxia, ascorbic acid, and α-tocopherol in iron-loaded rat myocardial cell cultures
54. Iron loading modifies the fatty acid composition of cultured rat myocardial cells and liposomal vesicles: Effect of ascorbate and α-tocopherol on myocardial lipid peroxidation
55. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: Studies in rat heart cells in culture
56. Iron loading modifies β-adrenergic responsiveness of cultured ventricular myocytes
57. Iron-loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility
58. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses
59. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation
60. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells